<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12320">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946554</url>
  </required_header>
  <id_info>
    <org_study_id>HEP101</org_study_id>
    <nct_id>NCT02946554</nct_id>
  </id_info>
  <brief_title>Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF</brief_title>
  <acronym>HEP101</acronym>
  <official_title>Multicenter Phase II Safety and Preliminary Efficacy Study of 2 Dose Regimens of HepaStem in Patients With Acute on Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promethera Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promethera Biosciences</source>
  <brief_summary>
    <textblock>
      The study will assess the safety of two dose regimens of HepaStem in Patients with ACLF up
      to Day 28 of the active study period.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by occurence of Adverse Events (AE) up to Day 28 of the active study period</measure>
    <time_frame>up to 28Day post first infusion day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by clinical parameters</measure>
    <time_frame>28Day, 3 month and 1 year post first infusion day</time_frame>
    <description>Clinical efficacy parameters evaluated by mortality, liver transplantation and disease scoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by biological parameters</measure>
    <time_frame>28Day, 3 month and 1 year post first infusion day</time_frame>
    <description>Biological efficacy parameters evaluated by bilirubin, creatinine, INR and albumin values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term safety Follow up assessed by the occurence of Adverse Event of Special Interest</measure>
    <time_frame>3 month and 1 year post first infusion day</time_frame>
    <description>Adverse Event of Special Interest defined as : SAE (Serious Adverse Event) with fatal</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>Low dose cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two dose regimens of HepaStem will be given, which differ in the amount of cells per infusion.
The low dose regimen will be given to the first cohort (first 6 patients included in the study).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The high dose regimen will be given to the second cohort after evaluation of the safety of the 1st cohort (stepwise approach)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HepaStem</intervention_name>
    <arm_group_label>Low dose cohort</arm_group_label>
    <arm_group_label>High dose cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Diagnosed cirrhosis

          -  ACLF Grade 1 or ACLF Grade 2 with no circulatory or respiratory failure.

        Main Exclusion Criteria:

          -  Absence of portal vein flow

          -  Known or medical history of thrombotic events

          -  Gastrointestinal hemorrhage requiring blood transfusion

          -  Septic shock or non-controlled bacterial infection

          -  Clinical evidence of aspergilus infection.

          -  Circulatory failure

          -  Respiratory disordered

          -  MELD score &gt; 35.

          -  Previous organ transplantation and/or ongoing immunosuppressive treatments.

          -  Renal failure due to chronic kidney disease.

          -  Clinically significant left-right cardiac shunt.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Gustot, MD</last_name>
      <email>thierry.gustot@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Thierry Gustot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KU Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederik Nevens, MD</last_name>
      <email>frederik.nevens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Frederik Nevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques St Luc</name>
      <address>
        <city>Woluwe-Saint Lambert</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Francois Laterre, MD</last_name>
      <email>pierre-francois.laterre@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Pierre-Francois Laterre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois DURAND, MD</last_name>
      <email>francois.durand@bjn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Francois Durand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier Samuel, MD</last_name>
      <email>didier.samuel@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Samuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>October 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute-On-Chronic Liver Failure</keyword>
  <keyword>ACLF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
